MedTrace Logo

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

NCT02526888 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-07-10

No results posted yet for this study

Summary

The main objective of this study is to investigate whether repeated administration of a cardiac medication (diltiazem) can affect the pharmacokinetics (i.e., amount and time of presence in the blood) of ACT-541468

Conditions

  • Healthy Subjects

Interventions

DRUG

ACT-541468

Oral capsule (25 mg) as single dose

DRUG

Diltiazem

Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Marie-Laure Boof, PhD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2015-11-01
Completion
2015-11-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526888 on ClinicalTrials.gov